金春股份(300877.SZ):擬斥2400萬元參設基金 專項投資“技源藥業”項目
格隆匯12月22日丨金春股份(300877.SZ)公佈,公司為充分提高資金使用效率,優化資源配置,提高資金盈利能力,更好的藉助專業投資機構的專業力量和風險控制體系,公司擬使用自有資金2400萬元與鴻富資產、江陰臨港創業投資有限公司、自然人劉一鳴、周曉亮、朱瑜、丁昌明、趙俊峯共同出資設立江陰源德創業投資合夥企業(有限合夥)(暫定名,最終以工商登記機關核定為準;簡稱“合夥企業”),合夥企業的規模為5201萬元。
該合夥企業僅專項投資“技源藥業”項目,即向江陰技源藥業有限公司(統一社會信用代碼:91320281741344724C)開展的股權投資或其他為前述股權投資而開展的投資行為。除“技源藥業”項目外,除非經全體合夥人一致同意,該合夥企業不再投資任何其他項目。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.